// App-Quantinova.ai

2588 : Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Researchers

Presenter

  • Antonio Risitano

Principal Investigators

  • Ilene C. Weitz

  • Carlos M. de Castro

  • Jean-Jacques Kiladjian

  • Morag Griffin

  • Hisakazu Nishimori

  • Mohamed Hamdani

  • Temitayo Ajayi

  • Scott B. Baver

  • Regis Peffault De Latour

Medical Centers

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • Jane Anne Nohl Division of Hematology, Keck School Of Medicine of USC, Los Angeles, CA

  • Duke University College of Medicine, Durham, NC

  • Centre d'Investigations Cliniques, Hôpital Saint-Louis; Assistance Publique – Hôpitaux de Paris; Université de Paris, Paris, France

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan

  • AMAG Pharmaceuticals, Inc., Waltham, MA

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

Locations

  • Italy

  • United States

  • France

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Anemia

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • Immunol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved